Pacira Unveils $200M Buyback, 2025 Revenue Hits $726.4M with 79.4% Margin
PCRX•Pacira highlighted record 2025 revenue of $726.4 million with GAAP gross margin of 79.4% and 22% total shareholder return since launching its 5x30 strategy in January 2025. It reported Q1 revenue of $143.3M for EXPAREL (+5%) and $26.8M for ZILRETTA (+15%), unveiled a $200M repurchase plus EXPAREL exclusivity to 2030.
1. Investor Presentation and Annual Meeting
Pacira posted an investor presentation in connection with its June 9, 2026 Annual Meeting, urging stockholders of record as of April 22, 2026 to vote for its six director nominees on the BLUE proxy card to support continued strategy execution.
2. Record 2025 Financial Results
In 2025, the company achieved total revenue of $726.4 million, GAAP gross margins of 79.4% and non-GAAP gross margins of 81.2%, and generated 22% total stockholder return since launching the 5x30 strategy in January 2025, marking the strongest performance in its history.
3. Sustained Q1 2026 Commercial Momentum
Pacira reported Q1 2026 revenue of $143.3 million for EXPAREL (+5% year-over-year), $26.8 million for ZILRETTA (+15%) and $6.2 million for iovera (+21%), reflecting continued demand growth across its commercial portfolio and successful execution of its non-opioid pain therapy strategy.
4. Share Repurchase and Patent Exclusivity
The board has returned $200 million to stockholders under a $300 million repurchase authorization and secured a volume-limited EXPAREL patent settlement that ensures market exclusivity through 2030, enhancing visibility into future cash flows and reinforcing long-term value creation.
